Lensar Inc Stock Price, News & Analysis

LENSAR (Nasdaq: LNSR) announced the granting of inducement awards to three newly-hired non-executive employees. The compensation package consists of 660 restricted stock units (RSUs) in total, approved by the independent members of LENSAR's board of directors.

The RSUs were granted on September 2, 2025, under LENSAR's 2024 Employment Inducement Incentive Award Plan. Each RSU represents one share of common stock and will vest in four equal annual installments, contingent upon continued employment with the company through each vesting date.

LENSAR (NASDAQ:LNSR) reported strong Q2 2025 results, highlighted by significant growth in its ALLY Robotic Cataract Laser Systems business. The company achieved total revenue of $13.9 million, up 10% year-over-year, driven by a 23% increase in worldwide procedure volumes.

Key highlights include 18 new ALLY Systems placements in Q2 with an additional 18 systems in backlog. The ALLY installed base grew 107% year-over-year to 165 systems, while the total combined installed base increased 23% to 410 systems. The company's recurring revenue reached 82% of total revenue.

LENSAR reported a net loss of $1.8 million ($0.15 per share), improved from a $9.0 million loss in Q2 2024. The company ended the quarter with $20.3 million in cash and investments. Notably, shareholders overwhelmingly approved the proposed merger with Alcon, with over 99% of votes in favor, expected to close by year-end.

LENSAR (Nasdaq: LNSR) announced the granting of inducement awards to three newly-hired non-executive employees. The compensation package consists of an aggregate of 660 restricted stock units (RSUs), approved by the independent members of LENSAR's board of directors.

The RSUs were granted on July 1, 2025, under LENSAR's 2024 Employment Inducement Incentive Award Plan. Each RSU represents one share of common stock and will vest in four equal annual installments, contingent upon continued employment with the company through each vesting date.

LENSAR (NASDAQ: LNSR) announced the granting of 3,090 restricted stock units (RSUs) to 10 newly-hired non-executive employees as employment inducement awards. The RSUs were granted on June 2, 2025, with approval from the majority of independent board members. Each RSU represents one share of common stock and will vest in four equal annual installments from the grant date, contingent on continued employment. The grants were made under LENSAR's 2024 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

LENSAR (NASDAQ: LNSR) reported strong Q1 2025 financial results, with total revenue reaching $14.2 million, a 34% increase from Q1 2024. The company placed 14 ALLY Robotic Laser Cataract Systems during the quarter, with an additional backlog of 24 systems pending installation. The total installed base grew to approximately 395 systems, a 26% year-over-year increase. Worldwide procedure volumes increased by 33%, with LENSAR systems performing about 22% of total U.S. procedures. Despite revenue growth, the company reported a net loss of $27.3 million, largely due to warrant liability changes following a 58% stock price increase. Notably, LENSAR announced a proposed merger with Alcon Research, LLC on March 24, 2025, receiving a $10 million cash deposit.

Alcon (NYSE: ALC) has announced a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR) in a deal worth up to $430 million. The acquisition includes LENSAR's ALLY Robotic Cataract Laser Treatment System, Streamline® software, and legacy laser system. Alcon will pay $14.00 per share in cash (approximately $356 million), with an additional contingent value right of up to $2.75 per share based on achieving 614,000 procedures between 2026-2027.

The deal represents a premium of 24% to LENSAR's 30-day VWAP and 47% to its 90-day VWAP. The acquisition strengthens Alcon's femtosecond laser-assisted cataract surgery (FLACS) portfolio and aims to expand advanced laser technology globally. With over 5 million cataract procedures in the U.S. and 32 million globally, the transaction is expected to close in mid-to-late 2025, subject to regulatory and stockholder approval.

Alcon (SIX/NYSE: ALC) has announced a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR), acquiring all outstanding shares at $14.00 per share in cash ($356 million), with an additional contingent value right of up to $2.75 per share based on procedure milestones, bringing potential total consideration to $430 million.

The acquisition includes LENSAR's ALLY Robotic Cataract Laser Treatment System, Streamline® software technology, and legacy laser system, strengthening Alcon's femtosecond laser-assisted cataract surgery (FLACS) portfolio. The deal offers a 24% premium to LENSAR's 30-day VWAP and 47% premium to 90-day VWAP.

With over 5 million cataract procedures in the US and 32 million globally, this acquisition aims to expand advanced femtosecond laser technology accessibility worldwide. The transaction is expected to close in mid-to-late 2025, subject to regulatory approval and LENSAR stockholder approval.

Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire LENSAR (NASDAQ: LNSR), strengthening its cataract equipment portfolio. The acquisition includes LENSAR's ALLY Robotic Cataract Laser System, Streamline software, and legacy laser system.

The deal values LENSAR at $14.00 per share in cash (approximately $356 million), with an additional contingent value right of up to $2.75 per share based on achieving 614,000 cumulative procedures between 2026-2027. The total potential consideration of $16.75 per share represents a 24% premium to LENSAR's 30-day VWAP and 47% to 90-day VWAP, potentially reaching $430 million.

The acquisition targets the growing cataract surgery market, with over 5 million procedures in the U.S. and 32 million globally. The transaction is expected to close in mid-to-late 2025, subject to regulatory approval and LENSAR stockholder approval.

LENSAR (NASDAQ: LNSR) has announced the granting of stock options to two newly-hired non-executive employees as employment inducements. The grants, approved by independent board members on March 3, 2025, allow the purchase of a total of 1,600 shares of common stock at $13.48 per share, matching the closing price on the grant date.

The options feature a vesting schedule where 25% vests after one year, followed by 36 monthly installments, contingent on continued employment. These 10-year term options were granted under LENSAR's 2024 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).